about
Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiologyCyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum.Targeting multidrug resistance in cancerTransport in technicolor: mapping ATP-binding cassette transporters in sea urchin embryos.Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium.Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.Abcb4 acts as multixenobiotic transporter and active barrier against chemical uptake in zebrafish (Danio rerio) embryos.Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter.Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study.Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages.Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.Functional expression of P-glycoprotein in Saccharomyces cerevisiae confers cellular resistance to the immunosuppressive and antifungal agent FK520.Design opportunities for actively targeted nanoparticle vaccines.Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier.Candida glabrata ATP-binding cassette transporters Cdr1p and Pdh1p expressed in a Saccharomyces cerevisiae strain deficient in membrane transporters show phosphorylation-dependent pumping properties.Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjects.ABC transporters at the blood-brain barrier.Nobiletin enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cancer cells.Reversal of multidrug resistance by novel nitrophenyl pyrones, SNF4435C and D.Evaluation of P-Glycoprotein Inhibitory Potential Using a Rhodamine 123 Accumulation AssayInteractions between P-glycoprotein and drugs used in the supportive care of acute myeloid leukemia patients.Lysosomotropic agents increase vinblastine efflux from mouse MDR proximal kidney cells exhibiting vectorial drug transport.Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.Molecular interactions of cyclosporin A with P-glycoprotein. Photolabeling with cyclosporin derivatives.Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line.Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells.Mechanisms of hepatic transport of cyclosporin A: an explanation for its cholestatic action?Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulationCircumvention of multi-drug resistance of cancer cells by Chinese herbal medicines.Identification and bioactive potential of endophytic fungi isolated from selected plants of the Western Himalayas.Selective inhibition of MDR1 P-glycoprotein-mediated transport by the acridone carboxamide derivative GG918.Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relationships with intrarenal angiotensin II deposits.11-Demethylcyclosporins exhibit a single conformation in methanol and dimethylsulfoxide.Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.Role of amino acid N-methylation in cyclosporins on ring opening and fragmentation mechanisms during collisionally induced dissociation in an ion trap.Colchicine myoneuropathy in a renal transplant patient.Optimizing the absorption of valspodar, a P-glycoprotein modulator, Part I: Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics.
P2860
Q28379120-EC85A8F3-5B28-4993-8D9E-9F824E6BA997Q28379469-003C1D9C-EB2E-4588-A193-09D521D9A2A8Q29616803-FF21264F-3828-4B68-9993-B29DDAFB8AE3Q34173709-AAFCBF35-2698-48BA-A63D-BB01D7D5D490Q34402344-12E14115-BD66-4B0C-ACE3-CB749C359D8FQ34448305-C0B7C281-6A63-4FA3-BE0B-0C6D20C268FDQ34775084-3086A1FE-09CD-4287-A309-3948FBA51D40Q34994901-AA6712D0-64A5-4062-ADF7-4AA38168955CQ35125010-E8AFBE29-DA9D-4B2F-9546-AEAF993430A5Q35796217-29B9E948-7525-4DEF-911D-B7594ED39B34Q36116213-A5D9202C-A13C-416B-A05C-44560BBFBF90Q36326210-C1B5F890-37D3-4544-9877-81E3E17EB40FQ36367680-5BFAABA4-7FAD-4664-B725-E8E0B88669D5Q36525551-AA9B2C4B-49D4-44E7-B32F-462F39461964Q36643297-E15B10FD-80F0-44E8-B78A-A092603C5055Q37062606-DBEF2EAF-A40C-480D-8CB2-78102AB455F7Q37855817-FE757B08-DE96-41EB-91B7-B20AD8BBD2C2Q38362728-ABC33105-1E31-4BF9-8095-60F35FB005C7Q38465517-33A350F6-3144-428E-B406-32A107457552Q38783122-1BBCA402-8824-4093-A28B-DFA391334848Q38810143-B5852BEE-5909-4FAF-82E4-2A6D0A98AD56Q39122325-C8A2F7CE-60F9-4EA2-B253-8E39D44D30A6Q39851426-F524561C-6C19-4F6D-B5D7-106F327B3DB0Q40769755-55797505-99E1-4736-9A42-B64DA85DA215Q40970475-DB994164-D0E4-46FA-9925-1E8872E49234Q40978951-9C4B703B-3548-4D9E-9439-68D01C86F758Q41121145-5FD91451-C967-4DDE-94DF-13A375290617Q41292266-1F9A9E3F-3B8E-4928-8C94-8BA29BABC6E9Q41483163-8BD97ADD-A79E-4E81-B7C1-E1112B37C44AQ41564063-B44131C5-38C7-4E3F-AA1A-2D094B87E5DEQ41907216-9076F4AE-011D-4556-9DD6-B2381A27794DQ41970695-C290AE59-B00A-42D9-920D-839BED5232DFQ42025107-393CB231-3F0A-47D5-A477-93BBA32DB5E6Q42029087-A084C2F7-4DEE-4491-B74D-23C826CE255DQ42839262-93BD98BA-DB02-4E79-BD5C-59781B8CB99DQ43750306-C8C6DA47-24C1-49E7-BD27-6FE5059D0EA2Q43925182-61BF5062-6797-4A27-8888-B06E962F8D24Q43938738-E60B1DC1-9876-4768-8C7B-02642232133CQ44067347-2B298A72-4365-424C-B13F-39AE30633C9EQ51571293-17575943-301C-4CAB-BF61-C2172FA2EE31
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Cyclosporins as drug resistance modifiers.
@ast
Cyclosporins as drug resistance modifiers.
@en
type
label
Cyclosporins as drug resistance modifiers.
@ast
Cyclosporins as drug resistance modifiers.
@en
prefLabel
Cyclosporins as drug resistance modifiers.
@ast
Cyclosporins as drug resistance modifiers.
@en
P1476
Cyclosporins as drug resistance modifiers.
@en
P2093
Twentyman PR
P304
P356
10.1016/0006-2952(92)90668-9
P407
P577
1992-01-01T00:00:00Z